Exelixis, Inc. financial data

Symbol
EXEL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1851 Harbor Bay Parkway, Alameda, CA
State of incorporation
DE
Fiscal year end
January 3
Latest financial report
10-K - Q4 2024 - Feb 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 382 % -8.38%
Quick Ratio 5.61 % -20%
Debt-to-equity 31 % +19.7%
Return On Assets 18.2 % +167%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 280M shares -7.69%
Common Stock, Shares, Outstanding 282M shares -6.96%
Entity Public Float 4.8B USD +2.13%
Common Stock, Value, Issued 282K USD -6.93%
Weighted Average Number of Shares Outstanding, Basic 290M shares -8.84%
Weighted Average Number of Shares Outstanding, Diluted 296M shares -7.88%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.17B USD +18.5%
Research and Development Expense 910M USD -12.8%
Costs and Expenses 1.56B USD -5.74%
Operating Income (Loss) 605M USD +254%
Income Tax Expense (Benefit) 160M USD +222%
Net Income (Loss) Attributable to Parent 521M USD +151%
Earnings Per Share, Basic 1.8 USD/shares +177%
Earnings Per Share, Diluted 1.76 USD/shares +171%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 217M USD -17.3%
Marketable Securities, Current 894M USD +22.1%
Inventory, Net 22.4M USD +29.2%
Assets, Current 1.47B USD +11.4%
Deferred Income Tax Assets, Net 420M USD +16.3%
Property, Plant and Equipment, Net 119M USD -7.26%
Operating Lease, Right-of-Use Asset 173M USD -26%
Goodwill 63.7M USD 0%
Assets 2.95B USD +0.18%
Accounts Payable, Current 38.2M USD +13.1%
Contract with Customer, Liability, Current 2.74M USD -49.3%
Liabilities, Current 404M USD +2.41%
Contract with Customer, Liability, Noncurrent 3.39M USD -38.6%
Operating Lease, Liability, Noncurrent 191M USD +0.46%
Other Liabilities, Noncurrent 109M USD +15.6%
Liabilities 703M USD +3.69%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.35M USD +64.1%
Retained Earnings (Accumulated Deficit) -98.6M USD +43.1%
Stockholders' Equity Attributable to Parent 2.24B USD -0.87%
Liabilities and Equity 2.95B USD +0.18%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 68.8M USD -18.5%
Net Cash Provided by (Used in) Financing Activities -184M USD -4113%
Net Cash Provided by (Used in) Investing Activities 112M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 282M shares -6.96%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.43M USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 217M USD -17.3%
Deferred Tax Assets, Valuation Allowance 86M USD +3.65%
Deferred Tax Assets, Gross 545M USD +9.46%
Operating Lease, Liability 216M USD +0.08%
Payments to Acquire Property, Plant, and Equipment 9.69M USD -19.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 524M USD +140%
Lessee, Operating Lease, Liability, to be Paid 286M USD -9.46%
Property, Plant and Equipment, Gross 220M USD +5.26%
Operating Lease, Liability, Current 25M USD -2.74%
Lessee, Operating Lease, Liability, to be Paid, Year Two 28.5M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 26.5M USD +0.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 69.9M USD -11.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 24.3M USD -7.2%
Deferred Tax Assets, Operating Loss Carryforwards 39.9M USD +35.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 128M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 25M USD -7.19%
Additional Paid in Capital 2.34B USD -3.97%
Depreciation, Depletion and Amortization 6.38M USD -6.96%
Deferred Tax Assets, Net of Valuation Allowance 459M USD +10.6%
Share-based Payment Arrangement, Expense 93.8M USD -11.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%